Current Oncology

7 pages, 3302 KB

Open AccessLetter

Early Prediction of Treatment Response in Advanced Gliomas with 18F-dopa Positron-Emission Tomography

by Nicholas Dowson, Paul Thomas, Michael Fay, Rosalind L. Jeffree, Yaniv Gal, Pierrick Bourgeat, Jye Smith, Craig Winter, Alan Coulthard, Olivier Salvado, Stuart Crozier and Stephen Rose

Curr. Oncol. 2014, 21(1), 172-178; https://doi.org/10.3747/co.21.1772 - 1 Feb 2014

Cited by 8 | Viewed by 843

Abstract

Imaging markers that enable prediction of survival are of interest for aiding clinical decision-making for patients with advanced glioma. [...] Full article

3 pages, 1363 KB

Open AccessArticle

“Bored Out of My Gourd”: A Cancer Survivor’s Return-to-Work Experience

by T. Morrison and R. Thomas

Curr. Oncol. 2014, 21(1), 169-171; https://doi.org/10.3747/co.21.1665 - 1 Feb 2014

Cited by 1 | Viewed by 832

Abstract

“The cancer had to accommodate my life. My life was not going to be built around this diagnosis.”[...] Full article

3 pages, 2426 KB

Open AccessCase Report

Thoracoscopic Surgery for Pulmonary Oncocytoma, an Uncommon Neoplasm

by B. Zhang, J. Jin, Z. Ye and H. Zheng

Curr. Oncol. 2014, 21(1), 166-168; https://doi.org/10.3747/co.21.1713 - 1 Feb 2014

Cited by 2 | Viewed by 799

Abstract

Oncocytoma is an uncommon neoplasm with a characteristic histologic feature of abundant eosinophilic granular cytoplasm. It almost always occurs in kidney, thyroid, or salivary gland. Pulmonary oncocytoma is a rare pulmonary neoplasm, with fewer than 10 cases reported so far in the available [...] Read more.

Oncocytoma is an uncommon neoplasm with a characteristic histologic feature of abundant eosinophilic granular cytoplasm. It almost always occurs in kidney, thyroid, or salivary gland. Pulmonary oncocytoma is a rare pulmonary neoplasm, with fewer than 10 cases reported so far in the available English literature. We encountered one such case that was successfully managed by thoracoscopic lobectomy. Full article

11 pages, 2264 KB

Open AccessArticle

Pseudomyxoma Peritonei Originating from Urachus—Case Report and Review of the Literature

by A.K. Agrawal, P. Bobiński, Z. Grzebieniak, J. Rudnicki, G. Marek, P. Kobielak, M. Kazanowski, S. Agrawal and A. Hałoń

Curr. Oncol. 2014, 21(1), 155-165; https://doi.org/10.3747/co.21.1695 - 1 Feb 2014

Cited by 45 | Viewed by 1164

Abstract

Pseudomyxoma peritonei (pmp) is a rare clinical condition defined as extensive intraperitoneal spread of mucus associated with a variety of mucinous tumours of varying biologic behavior. Although appendix or ovaries have usually been implicated as the primary site, cases have been [...] Read more.

Pseudomyxoma peritonei (pmp) is a rare clinical condition defined as extensive intraperitoneal spread of mucus associated with a variety of mucinous tumours of varying biologic behavior. Although appendix or ovaries have usually been implicated as the primary site, cases have been reported in association with neoplastic lesions of other sites. Pseudomyxoma peritonei originating from urachal remnants is a unique entity, reported only 18 times in the English literature thus far. Considering the rarity of the lesion, we report the case of a 50-year-old man surgically treated for pmp associated with a low-grade mucinous urachal neoplasm. Unique aspects of case are the low histologic aggressiveness of the causative lesion (reported only twice worldwide) and the early stage of the disease, with a relatively small amount of intraperitoneal free mucin. Review of the literature about pmp in general and a collation of previously reported cases of pmp originating from the urachus are presented and discussed. Full article

10 pages, 463 KB

Open AccessArticle

Oncofertility in Canada: cryopreservation and alternative options for future parenthood

by R. Ronn and H.E.G. Holzer

Curr. Oncol. 2014, 21(1), 137-146; https://doi.org/10.3747/co.20.1360 - 1 Feb 2014

Cited by 8 | Viewed by 1104

Abstract

Cancer can be a devastating diagnosis. In particular, malignancy and its indicated treatments have profoundly negative effects on the fertility of young cancer patients. Oncofertility has emerged as a new interdisciplinary field to address the issue of gonadotoxicity associated with cancer therapies and [...] Read more.

Cancer can be a devastating diagnosis. In particular, malignancy and its indicated treatments have profoundly negative effects on the fertility of young cancer patients. Oncofertility has emerged as a new interdisciplinary field to address the issue of gonadotoxicity associated with cancer therapies and to facilitate fertility preservation. In Canada, these fertility issues are often inadequately addressed despite the availability of resources. The goal of this four-part series is to facilitate systemic improvements in fertility preservation for adolescent and young adult Canadians with a new diagnosis of cancer. This article reviews fertility preservation options that use cryopreservation techniques. It also outlines some of the alternative options for future parenthood. Cryopreservation of a woman’s gametes and gonadal tissue may involve embryo, oocyte, and ovarian tissue cryopreservation with or without ovarian stimulation. Similarly, male gametes and gonadal tissue may be cryopreserved. Techniques and success rates continue to improve. Third-party assistance through gamete donation, gestational carriers, and adoption are also alternative options for parenthood. Cryopreservation techniques are especially feasible options for fertility preservation in the newly diagnosed cancer patient. Full article

7 pages, 1299 KB

Open AccessArticle

The Experience of Pain and Anxiety in Rectal Cancer Patients During High-Dose-Rate Brachytherapy

by S. Néron, S. Perez, R. Benc, A. Bellman, Z. Rosberger and T. Vuong

Curr. Oncol. 2014, 21(1), 89-95; https://doi.org/10.3747/co.21.1741 - 1 Feb 2014

Cited by 10 | Viewed by 897

Abstract

Background: Pain and anxiety have been reported as primary concerns for patients with head-and-neck, gynecologic, and prostate cancers undergoing high dose rate (hdr) brachytherapy. However, almost no research has been published on the degree to which these symptoms are experienced by [...] Read more.

Background: Pain and anxiety have been reported as primary concerns for patients with head-and-neck, gynecologic, and prostate cancers undergoing high dose rate (hdr) brachytherapy. However, almost no research has been published on the degree to which these symptoms are experienced by rectal cancer patients undergoing hdr brachytherapy. We conducted a pilot study examining the experiences of rectal cancer patients during hdr brachytherapy, specifically the intensity and trajectory of their anxiety and pain. Methods: Rectal cancer patients (n = 25) who received hdr brachytherapy treatment at a hospital in Montreal, Quebec, completed verbal analog scales for pain and anxiety at 4 time points over 4 treatment days. Results: On all 4 days, a subset of patients reported moderate-to-severe anxiety before applicator insertion. Pain increased significantly from the time patients were lying on the table to immediately after insertion of the applicator (p < 0.001). Insertion of the applicator appears to be the most painful part of the procedure, and although anxiety declined to below baseline after applicator removal, pain remained somewhat elevated. Some patients required conscious sedation; however, reports of moderate-to-severe pain were more frequent from patients who received pain medications than from patients who did not receive such medication (p < 0.05). Conclusions: Most patients with rectal cancer tolerated hdr rectal brachytherapy well, although the procedure is stressful and painful for some. Insertion of the applicator was found to be the point of maximal pain, and medication was not always completely successful at alleviating the pain, suggesting that additional psychosocial interventions might be needed, with particular emphasis on the time of applicator insertion. Full article

14 pages, 618 KB

Open AccessArticle

Oncology Education in Canadian Undergraduate and Postgraduate Medical Programs: A Survey of Educators and Learners

by V.C. Tam, S. Berry, T. Hsu, S. North, A. Neville, K. Chan and S. Verma

Curr. Oncol. 2014, 21(1), 75-88; https://doi.org/10.3747/co.21.1667 - 1 Feb 2014

Cited by 35 | Viewed by 1139

Abstract

Background: The oncology education framework currently in use in Canadian medical training programs is unknown, and the needs of learners have not been fully assessed to determine whether they are adequately prepared to manage patients with cancer. Methods: To assess the [...] Read more.

Background: The oncology education framework currently in use in Canadian medical training programs is unknown, and the needs of learners have not been fully assessed to determine whether they are adequately prepared to manage patients with cancer. Methods: To assess the oncology education framework currently in use at Canadian medical schools and residency training programs for family (fm) and internal medicine (im), and to evaluate opinions about the content and utility of standard oncology education objectives, a Web survey was designed and sent to educators and learners. The survey recipients included undergraduate medical education curriculum committee members (umeccms), directors of fm and im programs, oncologists, medical students, and fm and im residents. Results: Survey responses were received from 677 educators and learners. Oncology education was felt to be inadequate in their respective programs by 58% of umeccms, 57% of fm program directors, and 50% of im program directors. For learners, oncology education was thought to be inadequate by 67% of medical students, 86% of fm residents, and 63% of im residents. When comparing teaching of medical subspecialty–related diseases, all groups agreed that their trainees were least prepared to manage patients with cancer. A standard set of oncology objectives was thought to be possibly or definitely useful for undergraduate learners by 59% of respondents overall and by 61% of postgraduate learners. Conclusions: Oncology education in Canadian undergraduate and postgraduate fm and im training programs are currently thought to be inadequate by a majority of educators and learners. Developing a standard set of oncology objectives might address the needs of learners. Full article

5 pages, 553 KB

Open AccessArticle

Extracellular–to–Body Cell Mass Ratio and Subjective Global Assessment in Head-and-Neck Cancers

by T. Małecka–Massalska, A. Smoleń and K. Morshed

Curr. Oncol. 2014, 21(1), 62-66; https://doi.org/10.3747/co.21.1671 - 1 Feb 2014

Cited by 17 | Viewed by 1052

Abstract

Background: The ratio of extracellular mass to body cell mass (ecm/bcm), determined by bioelectrical impedance analysis, has been found to be a potentially useful indicator of nutrition status. Subjective global assessment (sga) is a subjective method [...] Read more.

Background: The ratio of extracellular mass to body cell mass (ecm/bcm), determined by bioelectrical impedance analysis, has been found to be a potentially useful indicator of nutrition status. Subjective global assessment (sga) is a subjective method of evaluating nutrition status in head-and-neck cancer. The present study was conducted to investigate the association between ecm/bcm and sga in head-and-neck cancer. Methods: Patients were classified as either well-nourished or malnourished by sga. Bioelectrical impedance analysis was conducted on a population of 75 patients with histologically confirmed head-and-neck cancer, and the ecm/bcm was calculated. Receiver operating characteristic curves were estimated using the nonparametric method to determine an optimal cut-off value of the ecm/bcm. Results: Compared with malnourished patients, those who were well-nourished had a statistically significantly lower ecm/bcm (1.11 vs. 1.28, p = 0.005). An ecm/bcm cut-off of 1.194 was 76% sensitive and 63% specific in detecting malnutrition. Conclusions: The ecm/bcm can be an indicator that detects malnutrition in patients with head-and-neck cancer. Further observations are needed to validate the significance of the ecm/bcm and to monitor nutrition interventions. Full article

3 pages, 911 KB

Open AccessEditorial

Examining Cancer-Risk Profiles for the Largest Metropolitan Areas across Canada

by K. DeCaria, R. Rahal, T. Forte, G. Lockwood, J. Xu, H. Bryant and

Curr. Oncol. 2014, 21(1), 51-53; https://doi.org/10.3747/co.21.1853 - 1 Feb 2014

Viewed by 637

Abstract

Because health behaviours can be influenced at many different levels, there is value in examining differences in risk factors and health behaviours between the largest cities in Canada. [...] Full article

7 pages, 1362 KB

Open AccessArticle

Optimizing Outcomes with Azacitidine: Recommendations from Canadian Centres of Excellence

by R.A. Wells, B. Leber, N.Y. Zhu and J.M. Storring

Curr. Oncol. 2014, 21(1), 44-50; https://doi.org/10.3747/co.21.1871 - 1 Feb 2014

Cited by 14 | Viewed by 1469

Abstract

Myelodysplastic syndromes (mdss) constitute a heterogeneous group of malignant hematologic disorders characterized by marrow dysplasia, ineffective hematopoiesis, peripheral blood cytopenias, and pronounced risk of progression to acute myeloid leukemia. Azacitidine has emerged as an important treatment option and is recommended by [...] Read more.

Myelodysplastic syndromes (mdss) constitute a heterogeneous group of malignant hematologic disorders characterized by marrow dysplasia, ineffective hematopoiesis, peripheral blood cytopenias, and pronounced risk of progression to acute myeloid leukemia. Azacitidine has emerged as an important treatment option and is recommended by the Canadian Consortium on Evidence-Based Care in mds as a first-line therapy for intermediate-2 and high-risk patients not eligible for allogeneic stem cell transplant; however, practical guidance on how to manage patients through treatment is limited. This best practice guideline provides recommendations by a panel of experts from Canadian centres of excellence on the selection and clinical management of mds patients with azacitidine. Familiarity with the referral process, treatment protocols, dose scheduling, treatment expectations, response monitoring, management of treatment breaks and adverse events, and multidisciplinary strategies for patient support will improve the opportunity for optimizing treatment outcomes with azacitidine. Full article

8 pages, 799 KB

Open AccessReview

A Canadian Perspective on the Safe Administration of Bendamustine and the Prevention and Management of Adverse Events

by J. Koolwine, T. Crosbie, G. Gazzé, R. Turner, J. Wiernikowski and W. Assaily

Curr. Oncol. 2014, 21(1), 35-42; https://doi.org/10.3747/co.21.1855 - 1 Feb 2014

Cited by 5 | Viewed by 862

Abstract

Although bendamustine has been used to treat lymphoproliferative disorders for decades, it has only recently been approved for use in Canada. Thus, Canadian recommendations on the administration of bendamustine and the management of common adverse events (aes ) are needed. This article [...] Read more.

Although bendamustine has been used to treat lymphoproliferative disorders for decades, it has only recently been approved for use in Canada. Thus, Canadian recommendations on the administration of bendamustine and the management of common adverse events (aes ) are needed. This article highlights effective management and assessment strategies recommended by Canadian nurses and pharmacists for the most common aes arising from the use of bendamustine in patients with chronic lymphocytic leukemia and indolent non-Hodgkin lymphoma. Those strategies include administering bendamustine over 60 minutes instead of 30 minutes, administering pre-medications to control infusion-related reactions and nausea, hydrating patients to minimize fatigue, and using free-flowing saline at the closest port to prevent phlebitis. Full article

8 pages, 1866 KB

Open AccessArticle

Piloting a Regional Collaborative in Cancer Surgery Using a “Community of Practice” Model

by M. Fung-Kee-Fung, R.P. Boushey, J. Watters, R. Morash, J. Smylie, C. Morash, C. DeGrasse and S. Sundaresan

Curr. Oncol. 2014, 21(1), 27-34; https://doi.org/10.3747/co.21.1663 - 1 Feb 2014

Cited by 42 | Viewed by 1196

Abstract

Background: Patients requiring assessment for cancer surgery encounter a complex series of steps in their cancer journey. Further complicating the process is the fact that care is often delivered in a fragmented, silo-based system. Isolated strategies to improve cancer outcomes within those [...] Read more.

Background: Patients requiring assessment for cancer surgery encounter a complex series of steps in their cancer journey. Further complicating the process is the fact that care is often delivered in a fragmented, silo-based system. Isolated strategies to improve cancer outcomes within those systems have had inconsistent results. Methods: A regional quality improvement collaborative was developed based on a community of practice (cop) platform, a hub-and-spoke infrastructure, and a regional steering committee linking cop improvement projects with affiliated hospitals and their strategic priorities. The cop provided an avenue for multidisciplinary teams to collect and compare their performance data and to institute regional standards through literature review, discussion, and consensus. Regional interdisciplinary teams developed a set of quality indicators linked to mutually agreed-upon care standards. A limited regional database supported feedback about performance against both provincial and regional standards. Results: The cop approach helped to develop a multihospital collaboration that facilitated care quality improvements on a regional scale, with clinical outcomes of the improvements able to be measured. The 9 participating hospitals delivered cancer surgery in the specific disease sites according to practitioner-developed and provincially- or regionally-generated care standards and clinical pathways. Compliance with provincial evidence-based clinical guidelines improved (20% increase in 2010–2011 compared with 2006–2007). Other significant improvements included standardization and implementation of regional perioperative pathways in breast, colorectal, and prostate cancer disease sites; rectal cancer surgery centralization; increased use of sentinel lymph node biopsies in breast cancer surgery; and decreased positive surgical margin rates in prostate cancer. Conclusions: Improved quality is likely a result of diverse confounding factors. The deliberately cultivated multihospital multidisciplinary cops have contributed to positive structural and functional change in cancer surgery in the region. This regional cop model has the potential to play an important role in the development of successful collaborations in care quality improvement. Full article

8 pages, 1481 KB

Open AccessArticle

Managing Treatment–Related Adverse Events Associated with Alk Inhibitors

by J.M. Rothenstein and N. Letarte

Curr. Oncol. 2014, 21(1), 19-26; https://doi.org/10.3747/co.21.1740 - 1 Feb 2014

Cited by 58 | Viewed by 1806

Abstract

Anaplastic lymphoma kinase (ALK) rearrangements have been identified as key oncogenic drivers in a small subset of non-small-cell lung cancers (xnsclcs). Small-molecule Alk kinase inhibitors such as crizotinib have transformed the natural history of nsclc for this subgroup of [...] Read more.

Anaplastic lymphoma kinase (ALK) rearrangements have been identified as key oncogenic drivers in a small subset of non-small-cell lung cancers (xnsclcs). Small-molecule Alk kinase inhibitors such as crizotinib have transformed the natural history of nsclc for this subgroup of patients. Because of the prevalence of nsclc, ALK-positive patients represent an important example of the paradigm for personalized medicine. Although Alk inhibitors such as crizotinib are well tolerated, there is a potential for adverse events to occur. Proactive monitoring, treatment, and education concerning those adverse events will help to optimize the therapeutic index of the drugs. The present review summarizes the management of treatment-related adverse events that can arise with Alk inhibitors such as crizotinib. Full article

11 pages, 446 KB

Open AccessArticle

Qualitative Evaluation of Care Plans for Canadian Breast and Head-and-Neck Cancer Survivors

by K. Collie, J. McCormick, A. Waller, C. Railton, L. Shirt, J. Chobanuk, A. Taylor, H. Lau, D. Hao, B. Walley, B. Kapusta, A.A. Joy, L.E. Carlson and J. Giese–Davis

Curr. Oncol. 2014, 21(1), 18-28; https://doi.org/10.3747/co.21.1698 - 1 Feb 2014

Cited by 23 | Viewed by 1262

Abstract

Background: Survivorship care plans (scps) have been recommended as a way to ease the transition from active cancer treatment to follow-up care, to reduce uncertainty for survivors in the management of their ongoing health, and to improve continuity of care. The [...] Read more.

Background: Survivorship care plans (scps) have been recommended as a way to ease the transition from active cancer treatment to follow-up care, to reduce uncertainty for survivors in the management of their ongoing health, and to improve continuity of care. The objective of the demonstration project reported here was to assess the value of scps for cancer survivors in western Canada. Methods: The Alberta CancerBridges team developed, implemented, and evaluated scps for 36 breast and 21 head-and-neck cancer survivors. For the evaluation, we interviewed 12 of the survivors, 9 nurses who delivered the scps, and 3 family physicians who received the scps (n = 24 in total). We asked about satisfaction, usefulness, emotional impact, and communication value. We collected written feedback from the three groups about positive aspects of the scps and possible improvements (n = 85). We analyzed the combined data using qualitative thematic analysis. Results: Survivors, nurses, and family physicians agreed that scps could ease the transition to survivorship partly by enhancing communication between survivors and care providers. Survivors appreciated the individualized attention and the comprehensiveness of the plans. They described positive emotional impacts, but wanted a way to ensure that their physicians received the scps. Nurses and physicians responded positively, but expressed concern about the time required to implement the plans. Suggestions for streamlining the process included providing survivors with scp templates in advance, auto-populating the templates for the nurses, and creating summary pages for physicians. Conclusions: The results suggest ways in which scps could help to improve the transition to cancer survivorship and provide starting points for larger feasibility studies. Full article

6 pages, 1971 KB

Open AccessArticle

Exploring a “community of practice” methodology as a regional platform for large-scale collaboration in cancer surgery—the Ottawa approach

by M. Fung-Kee-Fung, R.P. Boushey and R. Morash

Curr. Oncol. 2014, 21(1), 13-18; https://doi.org/10.3747/co.21.1662 - 1 Feb 2014

Cited by 28 | Viewed by 1012

Abstract

Pressing challenges have forced health care providers to rethink traditional silos and professional boundaries. Communities of practice (cops) have been identified as a means to share knowledge across silos and boundaries. However, clarity sufficient to enable their easy and uniform reproducibility is lacking, [...] Read more.

Pressing challenges have forced health care providers to rethink traditional silos and professional boundaries. Communities of practice (cops) have been identified as a means to share knowledge across silos and boundaries. However, clarity sufficient to enable their easy and uniform reproducibility is lacking, leading to a gap between cop conceptualization and implementation. This paper explores a cop structure and outlines a framework that is adaptable, measurable, and implementable across health disciplines in a regional cancer surgery program. Full article

4 pages, 380 KB

Open AccessEditorial

Prophylactic Bilateral Oophorectomy at Time of Hysterectomy for Women at Low Risk: Acog Revises Practice Guidelines for Ovarian Cancer Screening in Low-Risk Womena

by C.A. Larson

Curr. Oncol. 2014, 21(1), 9-12; https://doi.org/10.3747/co.21.1721 - 1 Feb 2014

Cited by 8 | Viewed by 842

Abstract

On March 9, 2010, Richard J. Ablin phd, who was much involved in the discovery of prostate-specific antigen (psa), made national news with his quote, in an Op-Ed piece published in The New York Times and a sub-sequent March 22, [...] Read more.

On March 9, 2010, Richard J. Ablin phd, who was much involved in the discovery of prostate-specific antigen (psa), made national news with his quote, in an Op-Ed piece published in The New York Times and a sub-sequent March 22, 2010, U.S. National Public Radio interview, that “It’s no better than a coin toss”—de-scribing the psa test’s ability to predict prostate cancer in men[...] Full article

7 pages, 1139 KB

Open AccessArticle

Diagnostic Value of Preoperative Serum Carcinoembryonic Antigen and Carbohydrate Antigen 19-9 in Colorectal Cancer

by E. Polat, U. Duman, M. Duman, A.E. Atici, E. Reyhan, T. Dalgic, E.B. Bostanci and S. Yol

Curr. Oncol. 2014, 21(1), 1-7; https://doi.org/10.3747/co.21.1711 - 1 Feb 2014

Cited by 41 | Viewed by 1612

Abstract

Background: Since the first introduction of tumour markers, their usefulness for diagnosis has been a challenging question. The aim of the present prospective study was to investigate, in colorectal cancer patients, the relationship between preoperative tumour marker concentrations and various clinical variables. Methods: [...] Read more.

Background: Since the first introduction of tumour markers, their usefulness for diagnosis has been a challenging question. The aim of the present prospective study was to investigate, in colorectal cancer patients, the relationship between preoperative tumour marker concentrations and various clinical variables. Methods: The study prospectively enrolled 131 consecutive patients with a confirmed diagnosis of colorectal carcinoma and 131 age- and sex-matched control subjects with no malignancy. The relationships of the tumour markers carcinoembryonic antigen (cea) and carbohydrate antigen (ca) 19-9 with disease stage, tumour differentiation (grade), mucus production, liver function tests, T stage, N stage, M stage were investigated. Results: Serum concentrations of cea were significantly higher in the patient group than in the control group (p = 0.001); they were also significantly higher in stage iii (p = 0.018) and iv disease (p = 0.001) than in stage i. Serum concentrations of cea were significantly elevated in the presence of spread to lymph nodes (p = 0.005) in the patient group. Levels of both tumour markers were significantly elevated in the presence of distant metastasis in the patient group (p = 0.005 for cea; p = 0.004 for ca 19-9). Conclusions: Preoperative levels of cea and ca 19-9 might provide an estimate of lymph node invasion and distant metastasis in colorectal cancer patients. Full article

Journal Menu

Journal Browser

Curr. Oncol., Volume 21, Issue 1 (February 2014) – 17 articles

Further Information

Guidelines

MDPI Initiatives

Follow MDPI